Weight Loss Patients Keep Pounds Off With Fewer GLP-1 Shots

Patients taking popular weight loss medications have discovered something their doctors are now confirming: you might not need weekly injections forever.

Dr. Mitch Biermann, an obesity specialist at Scripps Clinic in San Diego, kept hearing the same story. His patients were stretching out their GLP-1 shots to every two or three weeks after reaching their goal weight, and it was working.

"By the time the third person told me they were taking it every second or third week and still maintaining their weight, I started recommending it to other patients," Biermann said. He designed a study to test whether this patient-led discovery actually worked.

The results, published in the journal Obesity, tracked 34 patients for 36 weeks. Most kept their weight off after spacing out their injections. They also maintained health wins like lower blood pressure and better blood sugar control.

Only four patients gained weight back, and they simply returned to weekly shots. The key: patients only reduced their injection frequency after reaching their target weight and hitting a plateau.

Scott McMillin, 65, lost 20 pounds on weekly Wegovy shots and got his blood pressure and cholesterol into healthy ranges. When he tried stopping completely, he quickly regained 10 pounds. But switching to shots every two weeks? That worked perfectly.

"It made no difference for me whether I was taking injections every week or every two weeks," McMillin said. "I just thought, well, less is better."

The Bright Side

This research addresses the biggest concern patients have about these medications: the prospect of lifelong weekly treatments. Only 6 percent of Americans currently use GLP-1 drugs, even though 51 percent of adults meet eligibility criteria.

"The number one question patients give me about this drug is, 'Will I have to take this every week forever?'" Biermann said. Now there's evidence that the answer might be no.

The study was small and didn't include a control group for comparison. Experts emphasize that patients didn't quit the medications, they just took them less frequently at standard doses. And participants had already dropped from an average body mass index of 30 (the threshold for obesity) down to 25.2 (just overweight).

Dr. Fatima Stanford, an obesity specialist at Harvard Medical School, notes the study helps "reframe the conversation" around these medications. Chronic treatment doesn't necessarily mean maximum weekly dosing forever.

The extra weight patients lost during less frequent dosing came from fat, not muscle. Patients saw 17 different dosing intervals work, from every 10 days to every six weeks.

When Biermann presented his findings at the Obesity Society meeting in Atlanta, doctors packed the room, standing in the back to hear about it. For patients facing barriers like cost, access, and concerns about unknown side effects, this flexibility offers genuine hope.